Growth hormone body weight

There have been some concerns expressed regarding the possible health consequences in adulthood (endocrinological and reproductive outcomes) of early-life isoflavone exposure from soy-based infant formula. The daily exposure of infants to isoflavones in soy-based infant formulas is 6- to 11-fold higher on a body weight basis than the dose that has hormonal effects in adults consuming soy foods. " However, evidence from adult and infant populations indicates that dietary isoflavones in soy-based infant formulas do not adversely affect human growth, development, or reproduction. 

Sex differences in hormone concentrations have been investigated in 47 patients (21 men and 26 women) with schizophrenia or related psychoses who were using different neuroleptic drugs (757). The median daily dose and the median body weight-adjusted daily dose were twice as high in men as in women. However, neuroleptic drug-induced hyperprolactinemia was more frequent and occurred at a lower daily dose in women. The growth hormone concentration was normal in all patients. 

I would like the reader to stop and ponder something for a few minutes. If, in theory, an athlete controlled proportionately all anabolic, androgenic, and catabolic hormones and enzymes with dominance upon protein based tissue growth, then supplied a correct ratio of amino acids, carbohydrates, and fats, the athlete would increase in protein based mass at a rate of body weight x 1.818 g daily. So a 250 pound bodybuilder in theory could add 454.5g daily in lean tissue. Though some or most would not agree, I... 

Then, in the 1980s, GHB was endorsed by the health food industry as a growth hormone stimulator, and was marketed and sold to help body builders increase muscle mass and maintain weight. But, also, GHB was embraced as an aid in weight loss and as an over-the-counter sleep agent because of its sedative side effects. 

In a pharmacokinetic-based study by Hedin et al. [94], hGH was administered with a nasal permeation enhancer, sodium tauro-24,25-dihydrofusidate (STDHF), in patients deficient in growth hormone (GH) using a reprocessed lyophilized form of hGH. The lyophilized material was formulated with STDHF and all the subjects received the formulation by both the nasal and subcutaneous routes. The dose given by the subcutaneous route was a standard dose of O.lIU/kg body weight (BW), whereas three different doses (of 0.2,0.4, and 0.8 IU/kg BW) of the nasal formulation were given. As compared with the subcutaneous route, all three nasal formulations showed a rapid increase in the plasma levels of hGH, with Y rn ix being reached 15-25 min after administration, as compared with 3-4 h in the case of the subcutaneous route. However, the Cmax was higher in the case of the latter route, and the nasal formulations touched baseline after 3-4 h, as compared with 14-18 h after subcutaneous delivery. 

Melanocortins. This is a generic name for the peptide hormones, melanotropin and corticotropin, (ACTH, adrenocorticotropic hormone), because both hormones are formed in the anterior pituitary gland from the same melanocortin precursor. Melanotropin controls melanocyte growth and pigmentation. Corticotropin stimulates the production of glucocorticoids and mineralocorticoids, such as aldosteron, in the adrenal cortex. The Melanocortin-pathway is somehow involved in the control of appetite and body weight. 

The adverse effects of somatropin differ between adults and children. In adults, adverse effects are commoner in men, in heavier patients, and in adult-onset growth hormone deficiency. Efficacy is no greater in those who develop adverse effects. The higher rate of adverse effects is due to the higher dose of somatropin when calculated according to body weight, and also to lower sensitivity to somatropin in women than in men (2-4). Rapid dose... 

---